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In this study, we measured the serum concentration of TIMP-2 in patients with systemic sclerosis (SSc) and explored its possible
correlation with cardiac and pulmonary lesions. We studied 42 patients with SSc, with duration equal to or more than 2 years.
CT chest, ECG, echocardiography, and serum TIMP-2 concentration measurement using ELISA technique were performed in all
patientsandin25normalcontrols.ThemeanserumlevelsofTIMP-2inpatientswashigherthanincontrols(P = .005).Themean
CT score of dSSc patients with elevated TIMP-2 levels was signiﬁcantly higher than dSSc patients with normal levels (P = .013).
Four patients out of ﬁve with elevated TIMP-2 levels showed diastolic dysfunction (80%), compared to 2 out of 15 lSSc patients
with normal levels (13.3%), with P = .014. Our research, though involving a small group of patients, points to the probable role
of TIMP-2 in the development of pulmonary lesions in dSSc patients and cardiac lesions in lSSc patients with duration equal to or
more than 2 years.
Copyright © 2006 Amira Shahin et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
BACKGROUND
Systemic sclerosis (SSc) is an autoimmunological multisys-
tem disease aﬀecting the skin, dermal blood vessels, and in-
ternal organs. It is characterized pathologically by the over-
production of connective tissue and ﬁbrosis [1].
Fibrosis in the skin and internal organs in the course of
systemic sclerosis is caused by the accumulation of an exces-
sive quantity of collagen and other components of the extra-
cellular matrix (ECM) in the aﬀected area [2].
Fibroblasts play an important role in the metabolism of
extracellular matrix and connective tissue within the skin.
They produce matrix metalloproteinases (MMPs)—zinc-
dependent endopeptidases—which can digest all matrix
components. The ﬁbroblast also produce the speciﬁc in-
hibitors of MMPs, known as tissue inhibitors of matrix met-
alloproteinases (TIMPs) [3]. The quantity of ECM com-
ponents is thought to depend on the equilibrium between
MMPs and their inhibitors [4].
The results of the research evaluating the production
of collagen by the ﬁbroblast of SSc patients have also been
inconclusive.Someauthorshavedemonstratednormalfunc-
tioning in these cells, while others have found increased ﬁ-
broblast production of collagen [5, 6].
The role of TIMP-1 in the pathogenesis of SSc has been
well described in previous studies. Its levels in patients with
diﬀuse SSc (dSSc) were suggested to correlate with the pro-
gressive course of dermal ﬁbrosis seen in early disease [7–9].
TIMP-2 is an important member of the TIMPs. It was
demonstrated that an increased concentration of TIMP-2
may play a certain role in the development of SSc [9]. It was
also suggested that TIMP-2 may have a role in the pathogen-
esis of pulmonary ﬁbrosis in SSc [10].
The ﬁbrillar collagen matrix is an important constituent
of the left ventricular myocardium. It contributes to the
maintenance of left ventricular geometry and the structural
alignment of adjoining myocytes. MMP activity is tightly
controlled in normal myocardium by TIMPs. Increased my-
ocardial MMP activity has been reported to occur in both
clinical and experimental forms of dilated cardiomyopathy
[11–16].HigherserumlevelsofTIMP-2wereobservedinpa-
tients with SSc and cardiovascular changes [17].2 Mediators of Inﬂammation
The purpose of our research was to specify the depen-
dence between the serum concentration of TIMP-2 in pa-
tients with SSc and the pulmonary and cardiac dysfunction
as detected by CT, echocardiography, and ECG.
MATERIAL AND METHODS
Patients
Forty-two nonsmoking patients aﬀected by SSc, with dis-
ease duration equal to or more than 2 years, attending the
Rheumatology and Rehabilitation Department, Kasr Eleini
Hospital, were recruited in the recent study (thirty-three
women, mean age 42.2
￿ 11.3, range 19–65 years, and mean
disease duration 6.5
￿5.2 with range 2–25 years).
Twenty-twopatientshaddiﬀuseform(dSSc)(17women,
mean age 39.9
￿ 11.7 with range 19–58 years, and mean du-
ration 6.4
￿ 4.6 with range 2–18 years), and 20 patients had
limited form (lSSc) (16 women, mean age 44.7
￿ 9.9w i t h
range 19–65 years, and mean disease duration 6.6
￿ 5.8w i t h
range 2–25 years).
All patients met the American Rheumatism Association
preliminary criteria for diagnosis and classiﬁcation of SSc
[18], and the LeRoy et al criteria for subclassiﬁcation of SSc
[19].
Twenty-ﬁve normal nonsmoking volunteers (eighteen
women, mean age 42.9
￿ 12.0, ranging from 21–61 years)
were involved as controls.
All patients had complete clinical examination including
evaluationforgastrointestinal,pulmonary,cardiac,renaland
muscleinvolvement,inadditiontotheroutinelaboratoryin-
vestigations.
Antinuclear antibodies (ANA) were identiﬁed by the in-
direct immunoﬂuorescence method using HEp-2 cells as a
substrate. Anti-Scl-70 antibodies were identiﬁed by using
ELISA.
Drug treatment—during the period of observation and
collection of serum samples for testing—included calcium
channel blockers (26 patinets, 14 with dSSc), vasodilators (6
patients, 2 with dSSc), corticosteroids (20 patients,16 with
dSSC, 10–40mg/day), methotrexate (16 patients, 12 with
dSSc, 12.5–15mg/week), and cyclophosphamide (4 patient,
3 with dSSc, IV pulse/month).
Modiﬁed Rodnan skin thickness score was used to evaluate
the skin involvement. The body was divided into 17 regions
(face,anteriorchest,abdomen,upperarms,forearms,hands,
ﬁngers,thighs,legs,andfeet).Thedegreeofskininvolvement
in each region was scored from 0 to 3 (0 = normal skin, and
3 = extreme thickening) and then summing the score of all
the palpated sites [20].
Dopplerechocardiography
A two-dimensional method and Doppler echocardiography
technique were applied for all patients. Imaging was per-
formed with a Sonos 1000 equipped with 2.5-mHz phased
pulsed array transducers (Hewlett-Packard, USA).
High-resolutioncomputedtomography
Pulmonary interstitial disease was assessed by high-resolu-
tion computed tomography (HRCT) using Somatom Plus-S
(Siemens, Erlangen, Germany) CT units. The HRCT images
were divided into upper, middle, and lower areas. For each
area of the lung, the following scores were used and then
summed for each patient: 0 = no interstitial changes; 1 =
thickened septal lines, subpleural lines, parenchymal bands,
and subpleural cysts; and 2 = honey combing. Any HRCT
scoring above 0 was considered abnormal [21].
Serum levels of tissue inhibitor of metalloproteinases 2
(TIMP-2) was measured by using Biotrak TM TIMP-2
human ELISA system, supplied by Amersham Pharmacia
Bioteck. The assay is based on a 2-site ELISA sandwich for-
mat. Peroxidase-labeled Fab antibody to TIMP-2 is added to
standard sample and the mixture is incubated in microtitre
wells precoated with anti-TIMP-2 antibody. The amount of
peroxidase is determined by the addition of TMB substrate,
and the concentration of TIMP-2 in a sample is determined
by interpolation from a standard curve.
The cutoﬀ value at and above which the level was consid-
ered abnormal (2 SD above the mean in the control subjects)
for TIMP-2 was settled at 68.7ng/mL (mean serum level in
the controls was 39.1
￿14.8ng/mL).
Statisticalanalysis
The results were expressed as mean
￿ SD, and analyzed sta-
tistically by using the Mann-Witney test and Chi square with
Fisher exact test when appropriate. P value less than .05 was
regarded as statistically signiﬁcant.
RESULTS
The serum levels of TIMP-2 in the patients ranged from 23–
274ng/mL, and the mean concentration was 78.3
￿71.9ng/
mL, while in the controls it ranged from 23–73ng/mL, and
the mean concentration was 36.4
￿ 10.5ng/mL.Thediﬀer-
ence between the means of the patients and the controls was
statistically signiﬁcant (P = .005).
ThemeanconcentrationofTIMP-2inpatientswithdSSc
was 94.6
￿ 79.8ng/mL, with range 31–274ng/mL, with sig-
niﬁcant diﬀerence when compared to controls (P = .0007).
While the mean concentration in patients with lSSc was
61.3
￿58.5ng/mL with range 23–243ng/mL, without signif-
icant diﬀerence when compared to the controls (P = .051).
The diﬀerence between the mean concentrations of the dSSc
patients and the lSSc patients was nonsigniﬁcant (P>. 05).
Anticentromere antibodies were detected in 16 patients
(38.1%); allof themhadlSSc(80%ofthepatientswithlSSc).
While anti-Scl-70 antibodies were detected in 19 patients
(45.2%), 18 patients had dSSc (81.8% of patients with dSSc),
and 1 patient had lSSc (5% of patients with lSSc).
In patients with dSSc, a signiﬁcant positive correlation
was observed between the serum levels of TIMP-2 on the one
hand and the age of patients (P = .02) and CT score (P =
.05) on the other hand. In patients with lSSc, no signiﬁcantAmira Shahin et al 3
Table 1: Clinical and laboratory data of dSSc patients, dSSc patients with elevated levels of TIMP-2 (Group 1), and dSSc patients with
normal levels (Group 2).
Parameter dSSc patients (n = 22) Group 1 (n = 9) Group 2 (n = 13) P
Age (years)a 39.9
￿11.73 9 .9
￿6.13 9
￿16.2N S
Duration (years)a 6.4
￿4.65 .3
￿2.77 .2
￿5.8N S
ESRa 44.4
￿23.95 4 .3
￿30.23 3 .3
￿9.9N S
TIMP-2 (ng/ml)a 94.6
￿79.8 168.1
￿79.14 3 .7
￿10.6 P = .05
Rodnan skin scorea 19
￿9.12 2
￿11 17
￿7.3N S
Raynaud’s phenomenonb 18 (81.8) 7 (77.8) 11 (84.6) NS
Esophageal dysmotilityb 16 (72.7) 7 (77.8) 9 (69.2) NS
Telangectasiab 4 (18.2) 1 (11.1) 3 (23.1) NS
Hypertensionb 9 (40.9) 2 (22.2) 7 (53.9) NS
HRCT scorea 4.9
￿4.96 .1
￿5.72 .8
￿2.9 P = .05
Cardiac lesionb 7 (31.8) 4 (44.4) 3 (23.1) NS
Valvular lesionb 4 (18.2) 2 (22.2) 2 (15.4) NS
Diastolic dysfunctionb 1 (4.5) 1 (11.1) 0 NS
Conduction defect 2 (9.1) 1 (11.1) 1 (7.7) NS
Cardiomegally 2 (9.1) 1 (11.1) 1 (7.7) NS
Anti-Scl-70 18 (81.8) 8 (88.9) 10 (76.9) NS
A.centro.b 00 0 —
aMean
￿ SD.
bNumber (%).
dSSc: diﬀuse systemic sclerosis.
ESR: erythrocyte sedimentation rate.
A.centro.: anticentromere antibodies.
Mann-Whitney test, chi-square with Fisher’s exact test, and Student t test were used.
correlation was observed between TIMP-2 levels and any of
the other variables.
FourteenpatientsshowedelevatedserumlevelsofTIMP-
2 above the cutoﬀ value (9 patients had dSSc).
TIMP-2inpatientswithdSSc
Nine patients out of 22 with dSSc (40.9%) showed elevated
serum levels above the cutoﬀ value. Patients were divided
intotwogroups:patientswithelevatedserumlevelsofTIMP-
2 (group 1), and patients with normal levels (group 2).
T h em e a nd u r a t i o ni ng r o u p1w a s5 .3
￿2.7y e a r s( r a n g e
2–10 years). The mean duration of patients in group 2 was
7.2
￿ 5.8 (range 2–18 years), and the diﬀerence between the
two groups was nonsigniﬁcant (P>. 05).
ThemeanRodnanscoreofpatientsingroup1was22
￿11
(range 8–42), while in group 2 it was 17
￿ 7.3 (range 6–30),
and the diﬀerence was nonsigniﬁcant (P>. 05).
For all dSSc patients, the mean HRCT score was 4.9
￿4.9
(range 0–14). Six patients showed normal lungs by HRCT,
and the remaining 16 patients showed diﬀerent types of lung
lesions.
ThemeanCTscoreofthepatientsingroup1was6.1
￿5.7
(range0–14),andingroup2itwas2.8
￿2.9(range0–10),and
the diﬀerence between the two groups was signiﬁcant (P =
.013) (Figure 1).
The diﬀerence between the frequency of cardiac abnor-
malities in group 1 and group 2 was statistically nonsigniﬁ-
cant (Table 1).
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Figure 1: Linear regression line ﬁt plot showing the signiﬁcant re-
lation between TIMP-2 levels and CT score in DSSc patients.
No statistically signiﬁcant diﬀerence was found between
the two groups concerning any of the other disease’s param-
eters (Table 1).
TIMP-2inpatientswithlSSc
Five lSSc patients showed elevated serum levels of TIMP-2
above the cutoﬀ value. Patients with lSSc were further di-
vided into two groups: patients with elevated serum lev-
els of TIMP-2 (group 3), and patients with normal levels
(group 4).
Theduration ofdiseasein 5 patients ingroup 3wasmore
than 4 years, and the mean duration was 12.4
￿ 7.5y e a r s
(range 6–25 years). The mean duration of patients in group
4w a s4 .6
￿ 3.7 (range 2–12), and the diﬀerence between the
two groups was signiﬁcant (P = .014).4 Mediators of Inﬂammation
Table 2: Clinical and laboratory data of lSSc patients, lSSc patients with elevated levels of TIMP-2 (Group 3), and lSSc patients with normal
levels (Group 4).
Parameter lSSc patients (n = 20) Group 3 (n = 5) Group 4 (n = 15) P
Age (years)a 44.7
￿9.94 9 .2
￿10.64 3 .1
￿9.7N S
Duration (years)a 6.6
￿5.81 2 .4
￿7.54 .6
￿3.7 P=.014
ESRa 50.3
￿25.85 2
￿40.94 9 .7
￿20.7N S
TIMP-2 (ng/ml)a 61.3
￿58.5 145.4
￿65.63 3 .2
￿6.6 P = .05
Rodnan skin scorea 13.8
￿8.91 0 .6
￿2.11 1 .3
￿4.2N S
Raynaud’s phenomenonb 19 (95) 5 (100) 14 (93.3) NS
Esophageal dysmotilityb 15 (75) 4(80) 11 (73.3) NS
Telangectasiab 6 (30) 1 (20) 5 (33.3) NS
Hypertensionb 1( 5 ) 0 1( 6 . 7 ) N S
HRCT scorea 3.9
￿3.35 .4
￿3.33 .3
￿3.3N S
Cardiac lesionb 8 (40) 4 (80) 4 (26.7) NS
Valvular lesionb 5 (25) 1 (20) 4 (26.7) NS
Diastolic dysfunctionb 6 (30) 4 (80) 2 (13.3) P = .014
A.centro.b 16 (80) 4 (80) 12 (80) NS
aMean
￿ SD (range).
bNumber (%).
lSSc: limited systemic sclerosis.
ESR: erythrocyte sedimentation rate.
A.centro.: anticentromere antibodies.
Mann-Whitney test, chi-square with Fisher’s exact test, and Student t test were used.
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Figure 2: Linear regression line ﬁt plot showing the nonsigniﬁcant
relation between TIMP-2 levels and CT score in lSSc patients.
ThemeanRodnanscoreofpatientsingroup3was10.6
￿
2.1 (range 8–13), while in group 4 it was 11.3
￿4.2( r a n g e6 –
21), and the diﬀerence was nonsigniﬁcant (P>. 05).
For all lSSc patients the mean HRCT score was 3.9
￿ 3.3
(range 0–10). Six patients showed normal lungs by HRCT,
and the remaining 14 patients showed diﬀerent types of lung
lesions.
ThemeanCTscoreofthepatientsingroup3was5.4
￿3.3
(range 0–8), and in group 4 it was 3.3
￿ 3.3 (range 0–10),
and the diﬀerence between the two groups was nonsigniﬁ-
cant (P>. 05) (Figure 2).
Diastolic dysfunction was the commonest echocardio-
graphic ﬁnding found among patients with lSSc. Four pa-
tients out of ﬁve in group 3 showed diastolic dysfunction
(80%), compared to1 out of 15 in group 4 (13.3%) with
P = .014.ThelSScpatientwhohadthehighestTIMP-2levels
(243ng/mL) had left atrial and left ventricular hypertrophy.
One patient in group 3 had RBBB and LAHB.
No statistically signiﬁcant diﬀerence was found between
the two groups concerning any of the other disease’s param-
eters (Table 2).
DISCUSSION
In the recent study, we investigated the relation between the
serum levels of TIMP-2 and cardiac and pulmonary involve-
ment in SSc patients with duration equal to or more than 2
years.
There are many factors that aﬀect the development of
ﬁbrosis in scleroderma. Many studies pointed to the role
of metalloproteinases and their inhibitors in this process
[22–25]. More than 20 human metalloproteinases have been
described [26]. Among these metalloproteinases are colla-
genases, gelatinases, elastases, stromelisine, and membrane
metalloproteinases [27].
The production of metalloproteinases is regulated by cy-
tokines and growth factors. Their activity is also aﬀected by
TIMPs [28].
The quantity of ECM components is thought to depend
on the equilibrium between MMPs and their inhibitors, the
TIMPs. The disruption of this equilibrium is of essential
signiﬁcance both in the pathomechanism of physiological
processes such as healing of wounds or involution of the
uterus and in the process of angiogenesis as well as in certain
diseases such as tumor growth and metastasis [4].
MMPs and TIMPs may play an important role in various
rheumatic diseases. MMP-3 was suggested to be an impor-
tantfactorinthepathogenesisofsystemiclupuserythemato-
sus and rheumatoid arthritis. Serum MMP-9 activity in pa-
tients with diﬀuse cutaneous SSc was signiﬁcantly decreasedAmira Shahin et al 5
compared with that of limited cutaneous SSc or normal con-
trols [8]. The role of TIMP-1 in the pathogenesis of SSc has
been well described in previous studies. Increased levels of
both MMP-1 and TIMP-1 were found to be correlated with
the disease severity [7, 8]. TIMP-1 level was reported to be a
useful indicator of disease activity, especially of lung ﬁbrosis
[29].
The previous studies reported contradictory results con-
cerning the role of TIMP-2 in SSc patients. While Yazawa et
al demonstrated that Serum TIMP-2 level could be a useful
marker of the extent of skin sclerosis and disease activity and
the balance of TIMP-2 and MMP-2 might play an impor-
tant role in the pathogenesis of the disease [9]. Young-Min
et al found no diﬀerence in serum levels of TIMP-2 between
patients of SSc and controls [7].
The recent study showed a signiﬁcant diﬀerence between
patients and controls concerning the serum TIMP-2 levels
(P = .005), and this diﬀerence was more signiﬁcant when
comparing patients with dSSc and controls (P = .0007).
TIMPs were accused for being responsible for accelera-
tion of dermal ﬁbrosis in early stages of the disease. Zurita-
Salinas et al reported increased TIMP-1 levels in ﬁbrob-
lasts only from patients with early stages SSc [30]. Young-
Min have demonstrated that TIMP-1levels were signiﬁcantly
higher in early disease (< 2 years) than in late stage disease
(> 4 years) in patients with diﬀuse form of SSc [7].
In the recent study, the duration of disease in all patients
was equal to or more than 2 years to avoid considering skin
involvementasanassociatedfactor.Norelationwasreported
between the skin scoring and the serum TIMP-2 levels in this
study.ThedurationofdiseasewassigniﬁcantlylongerinlSSc
patients with elevated levels of TIMP-2 (group 3) compared
to lSSc with normal levels (group 4) with P<. 05.
No relation could be found between TIMP-2 levels and
anti-Scl-70 (anti-topoisomerase 1) nor anticentromere anti-
bodies.Kikuchietal[8]foundanassociationbetweenTIMP-
1 levels and anti-Scl-70. Young-Min et al [7] found no rela-
tionbetweenTIMP-1,TIMP-2,orMMP-1andanti-Scl-70or
anticentromere antibody.
MMPs and TIMPs have been shown to exist in various
tissues, including myocardium, and to be involved in colla-
gen remodeling [13–16]. TIMP-2 and TIMP-3 were found to
have important and unique roles in early cardiac develop-
ment [31]. Changes in the balance between matrix deposi-
tion and matrix degradation by MMPs and their inhibitors
TIMPs can lead to cardiac ﬁbrosis [32]. It was suggested that
MMPs could be responsible for induction of cardiac and
pulmonary lesions in patients with sarcoidosis by causing
damage to adjacent cardiac myocytes and pulmonary alveoli,
leading to the interstitial ﬁbrosis [33].
In the recent study, the mean lung CT score in dSSc pa-
tientswithelevatedTIMP-2levels(group1)wassigniﬁcantly
more than in patients with normal levels (group 2) (P =
.013). This ﬁnding supports the results of Dziankowska-
Bartkowiak et al [10] who suggested a possible role of TIMP-
2 in the development of pulmonary ﬁbrosis.
Diastolic dysfunction was the most common echocar-
diographic ﬁnding found among lSSc patients. Eighty % of
group 3 showed diastolic dysfunction compared to 13.3% of
group4withP = .014. Ithasbeen suggestedthatleftventric-
ular relaxation pattern is a feature of SSc [34, 35], and could
be explained by myocardial ﬁbrosis [36].
Cardiac involvement is not rare in SSc, and it may be pri-
mary or secondary to lung involvement [37–40]. The recent
ﬁndings suggest a probable role of TIMP-2 in the develop-
ment of myocardial ﬁbrosis in SSc patients. A higher serum
TIMP-2 levels were observed in a previous study in SSc pa-
tients with cardiovascular changes [17].
CONCLUSION
This study, though involving a small group of patients, con-
ﬁrms the observations made by other authors regarding the
probable role of TIMP-2 in inducing ﬁbrosis in the course of
SSc, and suggests a possible role of TIMP-2 in the develop-
ment of pulmonary involvement in dSSc patients, and car-
diac lesions in lSSc patients, with disease duration equal to
or more than 2 years.
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